other endpoints in screening studies for soft tissue sarcomas
DESCRIPTION
Other endpoints in screening studies for Soft Tissue Sarcomas. Jaap Verweij MD.PhD Dept of Medical Oncology Erasmus University Medical Center Rotterdam The Netherlands. Time. Surrogate Endpoint. Time. Disease. True Clinical Outcome. Intervention. Surrogate Endpoint. True Clinical - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/1.jpg)
Other endpoints in screening Other endpoints in screening studies for Soft Tissue Sarcomasstudies for Soft Tissue Sarcomas
Jaap Verweij MD.PhDJaap Verweij MD.PhD
Dept of Medical OncologyDept of Medical Oncology
Erasmus University Medical CenterErasmus University Medical Center
RotterdamRotterdam
The NetherlandsThe Netherlands
![Page 2: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/2.jpg)
TimeTime
DiseaseDisease
Surrogate
Endpoint
Surrogate
Endpoint
True Clinical
Outcome
True Clinical
Outcome
Time
Time
![Page 3: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/3.jpg)
DiseaseDisease
Surrogate
Endpoint
Surrogate
Endpoint
True Clinical
Outcome
True Clinical
Outcome
Intervention
![Page 4: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/4.jpg)
Question:Question:
If you know of all these ……… (Your Markers!)If you know of all these ……… (Your Markers!)
Would you be able to cure Would you be able to cure metastatic soft tissue sarcoma metastatic soft tissue sarcoma
(your ultimate aim)?(your ultimate aim)?
This is just a random selection of photographs. I apologize to This is just a random selection of photographs. I apologize to anyone who is not listedanyone who is not listed
![Page 5: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/5.jpg)
DiseaseDisease
Surrogate
Endpoint
Surrogate
Endpoint
True Clinical
Outcome
True Clinical
Outcome
Intervention
![Page 6: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/6.jpg)
We Should Desist Using RECISTat Least in GIST
Robert S. Benjamin, M.D.Department of Sarcoma Medical Oncology
The SARCOMA Center
+++++++
++ + +++ + + + + + ++ +++ ++++++++++++++ +++++++ + +++++++ ++
++
++++
+
+++ +
+ + +++ +
Months
Time to Progression - Nonresponders
302724211815129630
1
.9
.8
.7
.6
.5
.4
.3
.2
.1
0 Our Criteria n=17 RECIST n=54
p = 0.02
+ + ++++ +
++++++ +++ +
++++++ +++
++++ +++++++++++ +++
+ + ++++ +++++ ++ + ++++++++++++++ + +++++++++++++++++++++ ++
+++++++++++++++++++++++++ ++++
Months
Time to Progression - Responders
302724211815129630
1
.9
.8
.7
.6
.5
.4
.3
.2
.1
0
Our Criteria n=81 RECIST n=44
![Page 7: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/7.jpg)
It is easier It is easier to splice to splice an atom an atom than a than a
prejudiceprejudice
A.EinsteinA.Einstein
![Page 8: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/8.jpg)
How can we find How can we find the proof of the proof of concept:concept:
earlyearly
when tumors do when tumors do not shrink with not shrink with treatmenttreatment
??
![Page 9: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/9.jpg)
Screening for new drugs in STS
Are we looking Are we looking at the right at the right spot?spot?
![Page 10: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/10.jpg)
Which endpoint to use in Which endpoint to use in screening for new agents?screening for new agents?
Response rateResponse rate
Progression Free RateProgression Free Rate
Progression Arrest RateProgression Arrest Rate
TTP ratioTTP ratio
![Page 11: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/11.jpg)
Response RateResponse Rate Advantage: Advantage:
Response relatively easily measurableResponse relatively easily measurable
Disadvantage: Disadvantage: Does not take duration into account (DTIC 17%, Does not take duration into account (DTIC 17%,
duration 10 weeks)duration 10 weeks) Several cytotoxics discarded for response rate, Several cytotoxics discarded for response rate,
but high SD ratebut high SD rate May not be appropriate for new cytostatic agentsMay not be appropriate for new cytostatic agents
![Page 12: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/12.jpg)
0
10
20
30
40
50
60
70
80
1 2 3 4 5 6 7 8 9
time (months)
tum
ors
ize
SD
PR
Hypothetical tumor Hypothetical tumor evolution during treatmentevolution during treatment
![Page 13: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/13.jpg)
Is stable disease a Is stable disease a relevant achievement?relevant achievement?
i.e: CR+PR+i.e: CR+PR+SDSD
vs vs
PDPD
![Page 14: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/14.jpg)
(months)0 3 6 9 12 15
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk :
221 234 47 16 5 1
136 146 55 18 14 11
Inactive agents
Active agents
Progression free rateProgression free rate(2(2ndnd line treatment) line treatment)
Van Glabbeke et al, EJC 38:543-549,2002Van Glabbeke et al, EJC 38:543-549,2002
![Page 15: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/15.jpg)
Progression free rates (2Progression free rates (2ndnd line) line)
2 %2 %10 %10 %3 %3 %28 %28 %380380All patientsAll patients
33 %%1414 %%44 % %3939 %%146146ActiveActive
2 %2 %8 %8 %3 %3 %21 %21 %234234InactiveInactive
SESEEstim.Estim.SESEEstim.Estim.
6 months6 months3 months3 monthsNNType of drugType of drug
Van Glabbeke et al, EJC 38:543-549,2002Van Glabbeke et al, EJC 38:543-549,2002
![Page 16: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/16.jpg)
0
5
10
15
20
25
30
0 1 2 3 4 5
time (AU)
tum
ors
ize
Hypothetical tumor Hypothetical tumor evolution during evolution during
treatmenttreatmentTTP1TTP1
TTP2TTP2
If TTP2/TTP1 If TTP2/TTP1 >> 1.33: potentially active 1.33: potentially active agent*agent*
* Mick et al, Contr.Clin.Trials 21:343-359. 2000* Mick et al, Contr.Clin.Trials 21:343-359. 2000
![Page 17: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/17.jpg)
ET-743 as 3rd line ET-743 as 3rd line treatment inj soft tissue treatment inj soft tissue
sarcomasarcoma
Total populationTotal population Patients without tumor Patients without tumor regression but long regression but long
lasting stable diseaselasting stable disease
ASCO 2003, # ASCO 2003, # 32933293
![Page 18: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/18.jpg)
It could take long to assessIt could take long to assess
And in screening studies we would like And in screening studies we would like to know earlyto know early
The problem of durationThe problem of duration
![Page 19: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/19.jpg)
Using progression rateUsing progression rate
Set maximum PD rate Set maximum PD rate above which agent above which agent will be rejectedwill be rejected
PD rate of interest will depend on tumor PD rate of interest will depend on tumor typetype
TumorTumor RRRR PD ratePD ratebreastbreast >30%>30% <20%<20%
NSCLCNSCLC >20%>20% <30%<30%
GliomaGlioma >10%>10% <40% <40%
STSSTS >10%>10% <50% (??)<50% (??)
![Page 20: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/20.jpg)
0
10
20
30
40
50
60
70
80
90
100
Progressionarrest (%)
%%
Progression Arrest* RatesProgression Arrest* Rates
* Van Oosterom, In: Clinical Management of soft tissue * Van Oosterom, In: Clinical Management of soft tissue sarcomas. Martinus Nijhoff Publishers, 131-138, 1986sarcomas. Martinus Nijhoff Publishers, 131-138, 1986
![Page 21: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/21.jpg)
0102030405060708090
100
DX
TR
OF
OS
ET
-74
3
IFO
S
ES
O
TP
T
TX
T
GE
M
DT
IC
IMA
TIN
IB
IFN
-G
Mean%%
Progression Arrest RatesProgression Arrest Rates
![Page 22: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/22.jpg)
Response versus Symptom benefit rate*Response versus Symptom benefit rate*
0
20
40
60
Symptom benefit rate (%)0
20
40
60
250 mg 500 mg 250 mg 500 mg
Response Rate (%)
0
20
40
60
80
Response rate Symptom improvement rate
Response rate Symptom improvement rate
Gefitinib in NSCLCGefitinib in NSCLC
Imatinib in GISTImatinib in GIST
![Page 23: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/23.jpg)
ConclusionsConclusions
Aim of screening studiesAim of screening studies
To estimate a.s.a.p.if a drug may be To estimate a.s.a.p.if a drug may be useful for patientsuseful for patients
Endpoint for screening studiesEndpoint for screening studies
Progression free ratesProgression free rates
Progression arrest ratesProgression arrest rates
TTP ratioTTP ratio
Symptom improvement?Symptom improvement?
All of these require proper validationAll of these require proper validation
![Page 24: Other endpoints in screening studies for Soft Tissue Sarcomas](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56812b1e550346895d8f1692/html5/thumbnails/24.jpg)